<div id="readability-page-1"><div><p>As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that could impact small-cap stocks. In such an environment, identifying lesser-known companies with strong fundamentals and growth potential can be crucial for those looking to uncover hidden opportunities in the market.</p><h3>Top 10 Undiscovered Gems With Strong Fundamentals In The United States</h3><table><tbody><tr><th>Name</th><th>Debt To Equity</th><th>Revenue Growth</th><th>Earnings Growth</th><th>Health Rating</th></tr><tr><td>First Bancorp</td><td>75.89%</td><td>1.93%</td><td>-1.42%</td><td>★★★★★★</td></tr><tr><td>Senstar Technologies</td><td>NA</td><td>-18.50%</td><td>29.50%</td><td>★★★★★★</td></tr><tr><td>ASA Gold and Precious Metals</td><td>NA</td><td>12.79%</td><td>-0.59%</td><td>★★★★★★</td></tr><tr><td>Sound Financial Bancorp</td><td>34.70%</td><td>2.11%</td><td>-11.08%</td><td>★★★★★★</td></tr><tr><td>Affinity Bancshares</td><td>43.51%</td><td>4.54%</td><td>8.05%</td><td>★★★★★★</td></tr><tr><td>SUI Group Holdings</td><td>NA</td><td>16.40%</td><td>-30.66%</td><td>★★★★★★</td></tr><tr><td>Metalpha Technology Holding</td><td>NA</td><td>75.66%</td><td>28.60%</td><td>★★★★★★</td></tr><tr><td>Valhi</td><td>44.30%</td><td>1.10%</td><td>-1.40%</td><td>★★★★★☆</td></tr><tr><td>Rich Sparkle Holdings</td><td>26.73%</td><td>-6.13%</td><td>1.75%</td><td>★★★★★☆</td></tr><tr><td>Solesence</td><td>91.26%</td><td>23.30%</td><td>4.70%</td><td>★★★★☆☆</td></tr></tbody></table><p> Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener.     </p><p>Here's a peek at a few of the choices from the screener.</p><h2>Gyre Therapeutics (GYRE)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for anti-inflammatory and anti-fibrotic treatments targeting organ fibrosis, with a market cap of $650.32 million.</p><p><strong>Operations:</strong> Gyre Therapeutics generates revenue primarily through its Gyre Pharmaceuticals segment, which reported $102.19 million in revenue.</p><p>Gyre Therapeutics, a nimble player in the biotech scene, has recently become profitable, yet faces a forecasted earnings dip of 84.3% annually over the next three years. Despite this, revenue is expected to grow by nearly 17% per year. The company remains debt-free and boasts high-quality past earnings. Recent events include its addition to the S&amp;P Global BMI Index and leadership changes with Ping Zhang stepping in as interim CEO. For 2025, Gyre anticipates revenues between US$118 million and US$128 million, fueled by new product launches like Etorel and Contiva alongside ETUARY® sales.</p><ul><li>Unlock comprehensive insights into our analysis of Gyre Therapeutics stock in this health report.</li><li>Explore historical data to track Gyre Therapeutics' performance over time in our Past section.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth"/><figcaption>GYRE Earnings and Revenue Growth as at Sep 2025</figcaption></figure><h2>HarborOne Bancorp (HONE)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> HarborOne Bancorp, Inc. offers financial services to individuals, families, small and mid-size businesses, and municipalities with a market capitalization of $558.17 million.</p><p><strong>Operations:</strong> HarborOne Bancorp generates revenue primarily through HarborOne Bank, contributing $145.55 million, and HarborOne Mortgage with $19.35 million. The company exhibits a net profit margin trend worth noting for its implications on overall profitability.</p><p>HarborOne Bancorp, with total assets of US$5.6 billion and equity of US$580.1 million, showcases a robust financial foundation. Total deposits stand at US$4.5 billion against loans of US$4.7 billion, underlining strong lending activity supported by primarily low-risk funding sources—89% from customer deposits. The bank's allowance for bad loans is sufficient at 147%, with non-performing loans well-managed at 0.7%. Earnings have surged by 65.9% over the past year, notably outpacing the industry growth rate of 12.8%. Recently, HarborOne declared a quarterly dividend of $0.09 per share, reflecting its commitment to shareholder returns amidst steady earnings performance and high-quality earnings history.</p><ul><li>Take a closer look at HarborOne Bancorp's potential here in our health report.</li><li>Gain insights into HarborOne Bancorp's historical performance by reviewing our past performance report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth"/><figcaption>HONE Earnings and Revenue Growth as at Sep 2025</figcaption></figure><h2>Spok Holdings (SPOK)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> Spok Holdings, Inc. offers healthcare communication solutions globally through its subsidiary, Spok, Inc., and has a market capitalization of $358.90 million.</p><p><strong>Operations:</strong> Spok Holdings generates revenue primarily from its Clinical Communication and Collaboration business, amounting to $140.74 million.</p><p>Spok Holdings, a nimble player in the healthcare communication sector, is navigating a transition to a SaaS model, which is boosting its recurring revenue and margins. With no debt for five years and trading at 56.3% below its fair value estimate, Spok seems undervalued. The company reported Q2 2025 earnings with sales of US$17.25 million and net income of US$4.55 million, showing growth from the previous year. Despite these positives, challenges like declining wireless service revenue persist alongside modest projected annual growth of 1.1%. The stock's target price suggests potential upside from current levels around US$17.53 per share.</p><ul><li>Spok Holdings' transition to a SaaS model boosts recurring revenue and margins. Click here to explore the full narrative on Spok Holdings' strategic shift.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth"/><figcaption>SPOK Earnings and Revenue Growth as at Sep 2025</figcaption></figure><h2>Where To Now?</h2><ul><li>Investigate our full lineup of 286 US Undiscovered Gems With Strong Fundamentals right here.</li><li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li><li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li></ul><h2>Interested In Other Possibilities?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

GYRE

SPOK

<p>The U.S. market is experiencing volatility, prompting investors to seek lesser-known companies with strong fundamentals. Notable undiscovered gems include Gyre Therapeutics, HarborOne Bancorp, and Spok Holdings, each demonstrating growth potential despite market challenges. Gyre focuses on anti-inflammatory drugs, HarborOne offers financial services with a strong profit margin, and Spok is transitioning to a SaaS model for healthcare communication. These companies are highlighted for their robust financials and growth prospects, making them attractive options for investors looking for hidden opportunities in the market.</p>

Discovering 3 Undiscovered Gems In The US Market